Receptor News and Research

RSS

Once-daily oral treatment shows positive results in first human study for obesity treatment

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for the safe and effective redirection of nutrient absorption into the lower intestine, the weight loss and metabolic management mechanism behind gastric bypass surgery.

14 May 2025

Breast tissue changes could predict aggressive cancer and poor survival rates

Researchers at the National Institutes of Health (NIH) have identified a series of changes in the architecture and cell composition of connective tissues of the breast, known as stromal tissue, that is associated with an increased risk of developing aggressive breast cancer among women with benign breast disease, and poorer rates of survival among women with invasive breast cancer.

13 May 2025

Researchers unlock new paths toward treating stress-related psychiatric disorders

In a comprehensive Genomic Psychiatry review article published today, researchers from the University of Rochester Medical Center have synthesized decades of research on stress hormone systems in primate brains, potentially unlocking new paths toward treating stress-related psychiatric disorders.

13 May 2025

Simple oral swab test could revolutionize IVF success rates

About 15 per cent of all couples of reproductive age are involuntarily childless. A major reason why so many need assisted reproduction is that nowadays more and more people are putting off starting a family.

13 May 2025

Online obesity clinic achieves clinical trial-level weight loss with lower semaglutide doses

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online obesity clinic achieved similar weight loss to that reported in clinical trials – but with less than half the medication.

12 May 2025

RANBP2 identified as key regulator in the progression of multiple solid tumors

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

12 May 2025

Study shows cardiovascular benefits of GLP-1RAs in patients following bariatric surgery

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and diabetes following bariatric surgery who did not achieve sufficient weight loss and diabetes control, according to new research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain.

12 May 2025

GLP-1 drugs linked to significant BMI reduction in children with severe obesity

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at year's European Congress on Obesity (ECO 2025) suggests.

12 May 2025

Estrogen-related receptors could be a key to repairing energy metabolism and muscle fatigue

A new Salk Institute study suggests estrogen-related receptors could be a key to repairing energy metabolism and muscle fatigue.

12 May 2025

HER3 reemerges as a key driver of cancer progression and therapy resistance

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy.

12 May 2025

CAR-T cell therapy linked to brain fog in cancer patients

After treatment with CAR-T cells - immune cells engineered to attack cancer - patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating.

12 May 2025

Blood-based biomarkers predict therapy failure in prostate cancer patients

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients.

12 May 2025

Tirzepatide outperforms semaglutide for weight loss in people without diabetes

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide helped more participants reach key weight loss milestones, with manageable side effects and strong metabolic benefits.

12 May 2025

GLP-1RAs show added protection against cancer beyond weight reduction

New research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.

11 May 2025

New model reveals H5N1 is spreading undetected in US dairy herds

Researchers developed a nationwide model to simulate the spread of H5N1 in US dairy cattle, revealing significant under-reporting and predicting continued outbreaks into 2025. Targeted farm-level biosecurity and surveillance are urgently needed to contain the epidemic.

11 May 2025

New AI tool predicts viral mutations to help future-proof COVID vaccines

A novel AI-driven method helps scientists stay ahead of viral evolution by engineering synthetic spike proteins that anticipate future SARS-CoV-2 escape mutations, offering a powerful tool to test and strengthen next-generation vaccines.

11 May 2025

GLP-1 receptor agonists improve mood and metabolic health in adults with mental illness

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on mood, well-being, and quality of life in those both with and without mental illness, according to a systematic review of the available evidence being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May).

11 May 2025